QianJin Pharmaceutical(SH:600479) Ge Long Hui A P P·2026-02-09 09:03Core Viewpoint - Qianjin Pharmaceutical (600479.SH) reported a total operating revenue of 3.635 billion yuan for the fiscal year 2025, reflecting a year-on-year growth of 0.13% [1] - The net profit attributable to shareholders reached 288 million yuan, marking a year-on-year increase of 24.74% [1] - The net profit after deducting non-recurring gains and losses was 261 million yuan, up 19.48% year-on-year [1] - Basic earnings per share stood at 0.6414 yuan [1] Revenue and Profit Growth - The primary reasons for the company's revenue growth include stable revenue from core industrial enterprises and improved profitability [1] - The acquisition of stakes in two subsidiaries, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. (28.92% stake) and Hunan Qianjin Xieli Pharmaceutical Co., Ltd. (68% stake), contributed to the financial results as they were consolidated under the new ownership percentages starting in October and November 2025, respectively [1]